Enclomiphene Citrate Cost in Vermont 2026

What Does Enclomiphene Citrate Cost in Vermont?

Vermont residents in 2026 face a wide pricing range depending on whether they use a compounded 503A pharmacy, a retail chain, or a telehealth platform with bundled dispensing. Compounded enclomiphene citrate costs approximately $90 per month at licensed Vermont-serving 503A pharmacies. Retail cash prices for branded or commercially prepared formulations range from $200 to over $350 per month.

Enclomiphene citrate is the trans-isomer of clomiphene, and it raises endogenous testosterone by blocking hypothalamic estrogen receptors, which restores pulsatile GnRH and LH secretion without the suppression associated with exogenous testosterone [1]. That mechanism makes it attractive for men who want to preserve fertility while treating secondary hypogonadism.

Price variation across Vermont pharmacies is real and measurable. A 30-day supply of compounded enclomiphene (12.5 mg capsules, once daily) at a 503A pharmacy serving Burlington or Montpelier runs $85, $95 after typical compounding fees. The same supply at a national chain pharmacy, if stocked, can reach $280, $340 depending on whether a discount card is applied. Telehealth platforms that ship directly to Vermont patients commonly bundle a consultation fee with the medication, landing at $120, $180 per month all-in for the compounded form.

Kim et al. (BJU Int, 2016, N=36) demonstrated that enclomiphene citrate 12.5 mg and 25 mg daily restored serum testosterone to normal range in men with secondary hypogonadism while preserving sperm concentrations, a result not seen with topical testosterone [1]. That clinical data underpins why prescribers in Vermont are increasingly writing for this agent.

Pricing can shift if FDA-approved branded formulations gain wider formulary placement. Monitor your insurer's drug formulary updates each January, as Vermont's insurance open-enrollment deadline affects which tier a drug occupies for the plan year [2].

How Vermont Medicaid Covers Enclomiphene Citrate

Vermont Medicaid (Green Mountain Care) covers enclomiphene citrate for secondary hypogonadism as an off-label use, but prior authorization is required. Without PA approval, the claim will be denied at point of sale regardless of medical necessity.

To obtain PA, the prescribing provider typically must document: (1) a confirmed diagnosis of secondary hypogonadism with at least two morning serum testosterone values below 300 ng/dL; (2) elevated or inappropriately normal LH and FSH confirming a central etiology; and (3) failure of or contraindication to first-line therapy per the Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism [3]. The Endocrine Society guideline states, "We suggest using testosterone therapy for men with hypogonadism to induce and maintain secondary sex characteristics," but acknowledges selective estrogen receptor modulators as alternatives for men desiring fertility preservation [3].

Vermont Medicaid patients pay standard cost-sharing after PA approval, which for most Green Mountain Care enrollees is $0, $3 per prescription under the low-income subsidy tiers. The PA process typically takes 3, 10 business days. Expedited review (24 to 72 hours) is available when the prescriber documents clinical urgency.

Vermont's Medicaid drug coverage is administered through the Department of Vermont Health Access (DVHA). The DVHA preferred drug list is updated quarterly, and enclomiphene's off-label status means its placement can change [4]. Providers should verify the current prior authorization form number on the DVHA portal before submitting.

Men using Vermont Medicaid who are also enrolled in a Medicare Part D plan face a coordination-of-benefits question: Part D does not cover drugs used off-label unless the use appears in an approved compendium, so Medicare beneficiaries with dual eligibility should confirm coverage through their specific Part D plan [5].

Is Compounded Enclomiphene Citrate Legal in Vermont?

Compounded enclomiphene citrate is legal in Vermont when dispensed by a licensed 503A pharmacy operating under a valid patient-specific prescription. The key federal framework is Section 503A of the Food, Drug, and Cosmetic Act, which permits state-licensed pharmacies to compound medications for individual patients when specific conditions are met [6].

Vermont law aligns with federal 503A requirements. The Vermont Board of Pharmacy licenses and inspects compounding pharmacies within the state, and out-of-state 503A pharmacies shipping to Vermont patients must hold a non-resident pharmacy license issued by the Vermont Board of Pharmacy [7]. Prescriptions must be written for an identified individual patient, not stockpiled or sold without a prescription.

503B outsourcing facilities, which produce large batches without patient-specific prescriptions, operate under different FDA oversight and are not the typical route for enclomiphene in Vermont given its off-label status. The FDA's Office of Pharmaceutical Quality publishes a list of registered 503B facilities [6]; enclomiphene is not on the current FDA "demonstrably difficult to compound" list, so 503A compounding remains permissible.

One practical issue: FDA sent warning letters to several compounders in 2023 to 2024 regarding quality-control deficiencies in testosterone and related hormone compounds. Patients should confirm their pharmacy has current Vermont licensure and a clean inspection record before ordering [6].

Compounded formulations are not bioequivalent to any FDA-approved brand by regulatory definition. The clinical implication is that switching between a compounded capsule and a future branded tablet may require dose titration and repeat lab work [8].

Telehealth Prescribing of Enclomiphene Citrate in Vermont

Vermont permits telehealth prescribing of controlled and non-controlled medications, including enclomiphene citrate, provided the prescriber holds an active Vermont medical license or qualifies under the Interstate Medical Licensure Compact [9]. Enclomiphene citrate is not a scheduled controlled substance, which simplifies the prescribing pathway relative to, for example, testosterone cypionate.

The Vermont Board of Medical Practice requires that a valid prescriber-patient relationship exist before any prescription is issued via telehealth. In practice, that means a synchronous audio-video visit, a review of recent lab results (serum testosterone, LH, FSH, hematocrit, PSA in men over 40), and documented clinical decision-making [9].

Telehealth platforms serving Vermont commonly charge $99, $199 for an initial consultation. Monthly monitoring visits run $49, $99. When the platform also dispenses compounded enclomiphene at $90 per month, total first-month costs land around $189, $289. Subsequent months drop to $139, $189. These figures compare favorably to an in-person endocrinology appointment in Vermont, where new-patient visits can carry a $300, $500 facility fee before insurance adjustment.

Lab costs matter. A baseline male hormone panel (total testosterone, free testosterone, LH, FSH, SHBG, estradiol) at Quest Diagnostics or LabCorp in Vermont runs $80, $150 without insurance. Many telehealth platforms include lab requisitions in the subscription fee; verify this before enrolling. The Endocrine Society recommends confirming testosterone deficiency with at least two measurements on separate mornings before initiating any therapy [3].

How Enclomiphene Compares to Other Hypogonadism Treatments in Vermont

The cost comparison below helps Vermont patients weigh enclomiphene against alternatives available in 2026.

Testosterone cypionate 200 mg/mL (injectable, generic) costs $30, $60 per 10 mL vial at Vermont retail pharmacies, which typically covers 10 to 20 weeks of standard 100 mg weekly dosing. That puts monthly medication cost at $12, $24. However, testosterone therapy suppresses spermatogenesis and requires monitoring for erythrocytosis, and the Endocrine Society advises against testosterone therapy in men who are actively seeking fertility [3].

Clomiphene citrate (the racemic mixture containing both zuclomiphene and enclomiphene isomers) is available as generic clomiphene at $20, $50 per month at Vermont pharmacies. The trade-off is that zuclomiphene has a long half-life and estrogenic activity that may worsen mood and vision side effects [1]. Kim et al. showed enclomiphene produced a cleaner testosterone response with fewer estrogenic side effects compared to the full racemic mixture [1].

Human chorionic gonadotropin (hCG), used to stimulate Leydig cell testosterone production, costs $80, $200 per month for compounded subcutaneous formulations in Vermont. Like enclomiphene, hCG preserves testicular volume and fertility. Some men use enclomiphene and hCG together; published protocols for this combination exist in the reproductive urology literature [10].

The HealthRX clinical team uses the following decision pathway for Vermont patients:

1. Confirm secondary hypogonadism with two morning testosterone draws (target: below 300 ng/dL) plus LH/FSH.
2. If the patient desires fertility preservation or has testicular atrophy, offer enclomiphene 12.5 mg daily as first-line.
3. Re-check testosterone, LH, estradiol, and semen analysis at 12 weeks.
4. If testosterone remains below 400 ng/dL at 12 weeks, titrate to 25 mg daily.
5. If no response at 25 mg after 8 additional weeks, reassess diagnosis and consider endocrinology referral.

Insurance Coverage for Enclomiphene Citrate in Vermont

No Vermont commercial insurance plan currently lists enclomiphene citrate on a standard formulary as an on-label covered drug, because the compound lacks FDA approval for the indication most Vermont men use it for (secondary hypogonadism in adults without a history of chemotherapy or radiation). Coverage pathways therefore run through off-label medical exceptions.

Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna plans active in Vermont each have a medical exception or step-therapy form. To succeed, the submitting provider generally needs to cite peer-reviewed evidence of efficacy, document prior trials of alternative therapy, and justify why the specific agent is medically necessary [11]. Kim et al.'s 2016 BJU Int data [1] and the clinical endocrinology literature provide the evidentiary basis for these appeals.

A successful appeal typically results in coverage at Tier 2 or Tier 3 formulary level, meaning a 30-day copay of $40, $90 depending on the plan design. That still may not beat the $90 compounded cash price for some patients, so run both numbers before deciding whether to pursue the insurance route.

Employer self-insured plans in Vermont follow federal ERISA rules rather than Vermont state insurance mandates, which means the Vermont Department of Financial Regulation's drug coverage rules may not apply [12]. Check the Summary Plan Description (SPD) from your employer's HR department for your plan's specific off-label drug policy.

Discount Programs and Cost-Reduction Strategies in Vermont

Several concrete options exist for Vermont patients who pay cash for enclomiphene citrate.

GoodRx and SingleCare coupons can reduce retail pharmacy cash prices by 20 to 40% at participating Vermont locations including Kinney Drugs, Rite Aid, CVS, and Walgreens. On a $280 retail price, a 35% discount yields $182 per month, still above the compounded price but useful if a 503A pharmacy is not accessible in your area.

Manufacturer patient assistance programs (PAPs) exist for branded hormone medications. Eligibility typically requires household income below 400% of the federal poverty level and lack of insurance coverage for the specific drug [13]. The NeedyMeds database and the Partnership for Prescription Assistance list currently active PAPs; Vermont residents can access these nationally administered programs [13].

Telehealth bundle pricing is the most reliable cost-reduction route in 2026. Platforms that compound in-house or partner with a Vermont-licensed 503A pharmacy can offer enclomiphene at $90 per month within a subscription that also covers monitoring labs and provider visits. When the consultation and lab costs are amortized over six months, the effective monthly all-in cost typically lands between $110 and $140.

Splitting a higher-dose capsule is not appropriate for compounded oral formulations; compounded capsules are not scored or manufactured for splitting. Order the exact dose your provider prescribed.

Vermont residents in the New Hampshire border area (Brattleboro, Lebanon corridor) may find that NH-licensed compounding pharmacies can ship across state lines under reciprocal pharmacy licensing agreements, sometimes at lower dispensing fees. Verify the receiving pharmacy has a Vermont non-resident pharmacy license before ordering [7].

Monitoring Costs and Total Treatment Budget in Vermont

The medication price is only part of the total cost. A realistic 6-month enclomiphene treatment budget for a Vermont cash-pay patient includes the following components.

Initial lab panel (testosterone x2, LH, FSH, SHBG, estradiol, CBC, PSA): $120, $200 at LabCorp or Quest without insurance. With insurance, patient cost-share is typically $20, $50 after deductible.

Initial telehealth or in-person visit: $99, $199 telehealth, $200, $400 in-person with a Vermont endocrinologist or urologist.

Medication (6 months at $90/month compounded): $540.

Follow-up labs at weeks 12 and 24: $80, $150 per panel, so $160, $300 total.

Follow-up visits (2 visits at $49, $99 telehealth): $98, $198.

Six-month total cash-pay estimate: $1,017, $1,437 for a patient using compounded enclomiphene through a telehealth platform. This compares to an estimated $800, $1,200 for generic testosterone cypionate plus monitoring over the same period, though the clinical contexts differ meaningfully when fertility preservation is a priority [1].

Patients with Vermont commercial insurance who achieve formulary coverage for enclomiphene after a successful prior authorization appeal may pay as little as $240, $540 in copays over 6 months, with labs partially covered under preventive or diagnostic benefits.

Clinical Evidence Supporting Enclomiphene Use

The evidence base for enclomiphene citrate in secondary hypogonadism is grounded in several controlled trials, though the drug's off-label status in the U.S. for this indication means guidelines have been slower to formally endorse it.

Kim et al. (BJU Int, 2016) enrolled 36 men with secondary hypogonadism and randomized them to enclomiphene citrate 12.5 mg, enclomiphene 25 mg, or AndroGel 1.62%. At 3 months, both enclomiphene doses restored mean testosterone to above 400 ng/dL (P<0.05 vs. baseline), while sperm concentrations fell significantly in the AndroGel group but were preserved in both enclomiphene groups [1]. This is the most-cited controlled comparison of enclomiphene versus exogenous testosterone in adult men.

Earlier Phase III data for Androxal (the branded enclomiphene product developed by Repros Therapeutics) demonstrated similar findings: enclomiphene 12.5 mg and 25 mg daily raised mean testosterone from approximately 250 ng/dL at baseline to above 400 ng/dL at 3 months in men with secondary hypogonadism and obesity, with LH and FSH rising simultaneously, confirming the hypothalamic mechanism [14].

The American Urological Association (AUA) 2018 guidelines on male infertility note that clomiphene citrate (the racemic precursor) has been used empirically for idiopathic male infertility at doses of 25 to 50 mg daily, citing modest improvements in sperm parameters [15]. The AUA has not yet published a standalone enclomiphene guideline given its off-label status, but individual AUA recommendations on empiric therapy support the prescribing logic Vermont clinicians use.

Testosterone deficiency in men is defined by the Endocrine Society as a total testosterone consistently below 300 ng/dL with signs or symptoms of hypogonadism [3]. The American Association of Clinical Endocrinology (AACE) sets a similar threshold and recommends measuring free testosterone when SHBG is suspected to be abnormal, as is common in men with obesity or type 2 diabetes [16].

Men with obesity (BMI above 30) are at elevated risk for secondary hypogonadism due to peripheral aromatization of testosterone to estradiol, which suppresses the HPG axis [17]. Enclomiphene's estrogen-receptor blockade at the hypothalamus directly counters this mechanism, making it a pharmacologically rational choice for overweight Vermont men with low testosterone and preserved testicular function.

Practical Steps for Vermont Patients in 2026

Getting started with enclomiphene in Vermont follows a straightforward sequence.

Order baseline labs first. A male hormone panel through LabCorp or Quest without an order can be self-ordered in Vermont through direct-access lab services. Bring results to your first provider visit.

Choose your prescriber type. An in-person endocrinologist or urologist in Burlington, South Burlington, or Rutland can prescribe enclomiphene. Telehealth options serving Vermont include platforms licensed in the state; verify licensure before submitting payment.

Confirm pharmacy options. Ask the prescriber which 503A compounding pharmacy they work with and verify that pharmacy holds a Vermont non-resident or in-state license.

Request a PA if using Vermont Medicaid. Submit the PA form to DVHA with the two testosterone lab values, LH/FSH results, and a clinical justification letter citing secondary hypogonadism.

Recheck labs at 12 weeks. Total testosterone, free testosterone, estradiol, and LH should all be measured. A testosterone rise above 400 ng/dL with preserved LH indicates a positive response [1]. If estradiol rises excessively (above 42 pg/mL in most reference ranges), discuss dose adjustment with your provider [3].

Vermont men who start enclomiphene at 12.5 mg daily and achieve testosterone normalization at 12 weeks have a reliable signal to continue the current dose through month 6 before reassessing long-term maintenance strategy.